Soleno Therapeutics Inc.
Soleno Therapeutics Reports Serious Adverse Event to FDA
Summary
Soleno Therapeutics, Inc. disclosed that a serious adverse event, the death of a 17-year-old male patient with significant comorbidities, has been reported in the FDA's Adverse Event Reporting System (FAERS). The patient, who was not related to VYKAT XR treatment according to the company, died from an apparent pulmonary embolus. The company maintains that VYKAT XR has a proven safety and efficacy profile and will only comment on adverse events that are directly related to the drug use and unexpected according to its U.S. Prescribing Information.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement